Drug Type Small molecule drug |
Synonyms KMO inhibitor(Kynos Therapeutics), Kynurenine 3-monooxygenase inhibitor(Kynos Therapeutics) |
Target |
Mechanism KMO inhibitors(kynurenine 3-monooxygenase inhibitors) |
Therapeutic Areas- |
Active Indication- |
Inactive Indication- |
Originator Organization |
Active Organization Kynos Therapeutics Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Start Date10 Jan 2023 |
Sponsor / Collaborator Kynos Therapeutics Ltd.Startup |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Not Applicable | Renal transplant rejection Kynurenine 3-monooxygenase (KMO) | indoleamine 2,3-dioxygenase (IDO) | - | tlchzagoyi(rekwwylxhg) = The addition of 3HK completely restored E-cadherin and TJP1 expression djwxoqcjpw (bxnkqvkrrs ) View more | Positive | 05 Nov 2019 | ||
Not Applicable | - | fxlgtlgsmt(knwcuyamon) = 3HK inhibited proliferation of active Tcells and promoted Tcell injury and death. The same and higher concentrations of 3HK had no effect on cortical Epi and Endo cells jxxodfoobh (vfylytkuei ) | Positive | 23 Oct 2018 | |||